Request a FREE Sample of our FcRn Binding Kit!
Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one.
Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products!
Request a FREE sample of our GMP products!
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
AN3-H5253 | Human | Human Angiopoietin-like 3 / ANGPTL3 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
AN3-H52H3 | Human | Human Angiopoietin-like 3 / ANGPTL3 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
AN3-M52H3 | Mouse | Mouse Angiopoietin-like 3 / ANGPTL3 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
AN3-H82E7 | Human | Biotinylated Human Angiopoietin-like 3 / ANGPTL3 Protein, His,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
AN3-H5226 | Human | Human Angiopoietin-like 3 / ANGPTL3 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
Immobilized Human Angiopoietin-like 3, His Tag (Cat. No. AN3-H52H3) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human ANGPTL3 Antibody, Human IgG1 with a linear range of 0.5-2 ng/mL (QC tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Evinacumab | REGN-1500 | Approved | Regeneron Pharmaceuticals Inc | Evkeeza | United States | Hypercholesterolemia; Homozygous familial hypercholesterolemia | Regeneron Pharmaceuticals Inc | 2021-02-11 | Homozygous familial hypercholesterolemia; Hypertriglyceridemia; Hypercholesterolemia; Metabolic Diseases | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Plozasiran | ARO-APOC3 | Phase 3 Clinical | Arrowhead Pharmaceuticals Inc | Hypertriglyceridemia; Hyperlipoproteinemia Type I; Dyslipidemias | Details |
LNA-043 | LNA-043 | Phase 2 Clinical | Novartis Pharma Ag | Knee Injuries; Osteoarthritis, Knee; Osteoarthritis | Details |
Vupanorsen | ISIS-703802; PF-07285557 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Hypertriglyceridemia; Homozygous familial hypercholesterolemia; Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Hyperlipoproteinemia Type I; Hyperlipoproteinemias; Dyslipidemias; Cardiovascular Diseases; Hyperlipidemias; Hyperlipoproteinemia Type II | Details |
SHR-1918 | SHR-1918; SHR1918 | Phase 2 Clinical | Beijing Suncadia Medicine Co Ltd | Homozygous familial hypercholesterolemia; Hyperlipidemias | Details |
LY-3561774 | LY-3561774; DCR-CM-1; DCR-CM1 | Phase 2 Clinical | Dicerna Pharmaceuticals Inc | Metabolic Diseases; Dyslipidemias; Hyperlipoproteinemias; Cardiovascular Diseases; Lipid Metabolism Disorders | Details |
Zodasiran | ARO-ANG3; VSA-003(Arrowhead Pharmaceuticals) | Phase 2 Clinical | Arrowhead Pharmaceuticals Inc | Homozygous familial hypercholesterolemia; Hypertriglyceridemia; Dyslipidemias; Hyperlipoproteinemia Type II | Details |
LY-3475766 | LY-3475766 | Phase 1 Clinical | Eli Lilly And Company | Dyslipidemias | Details |
JS-401 | JS-401 | Phase 1 Clinical | Shanghai Junshi Biological Engineering Co Ltd | Hyperlipidemias | Details |
AZD-1705 | AZD1705; AZD-1705 | Phase 1 Clinical | Parexel, Astrazeneca Plc | Cardiovascular Diseases | Details |
This web search service is supported by Google Inc.